ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Sales of Investments

Cash received from selling or redeeming investments.

ImageneBio IncNASDAQ: IMA

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $10.5M fell 58.2% year over year, ahead of the -106.7% change in trailing-twelve-month sales of investments. Sequentially, it rose 39.1% from the prior quarter. Over 3 fiscal years it compounded at -56.4% a year.

Context

  • Sales of investments amounted to 1224.9% of revenue in FY2025, down 502.6 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -58.2% holds above the trailing-twelve-month pace of -106.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.5M+39.1% QoQ
Last fiscal yearDec 2025
$9.8M-83.8% YoY
LTMMar 2026
-$4.82M-106.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.2%——
1 year-83.8%——
3-year CAGR-56.4%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
9.8M USD
Year-over-year change
-83.8%

Sales of Investments vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -106.7% is the lowest of 7, against a peer median of -51.5%.
  • Over three fiscal years its annual growth of -56.4% compares with a peer median of -17.3%.
IMA Competitors
Sales of Investments for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$263.81M USD-56.8%+18.0%264.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$103.87M USD+49.8%——
STTKShattuck Labs, Inc.LTM Mar 2026$43.92M USD-54.1%-43.1%4391.5%
OVIDOvid Therapeutics Inc.LTM Mar 2026$42M USD-61.1%-22.4%589.7%
CNTBConnect Biopharma Holdings LimitedFY2025$39.95M USD+216.4%+5.0%62417.2%
IFRXInflaRx N.V.LTM Mar 2026€38.23M EUR-49.0%-17.3%130343.0%
KLRSKalaris Therapeutics IncLTM Mar 2026$35M USD———
IMAImageneBio IncLTM Mar 2026$4.82M USD-106.7%-56.4%—
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding IMA) —-51.5%-17.3%4391.5%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.12M)(68.77M)(68.17M)(49.23M)(52.4M)
Depreciation & Amortization544K751K1.02M490K328K
Deferred Income Tax00000
Stock-Based Compensation5.18M7.53M05.3M15.39M
Change in Working Capital(33.03M)(15.14M)(21.67M)(3.98M)(19.19M)
Accounts Receivables361K(291K)000
Inventory00000
Accounts Payables00(2.87M)(1.17M)(2.82M)
Other Working Capital(33.39M)(14.85M)(18.8M)(2.81M)(16.37M)
Other Non-Cash Items1.17M1.52M9.07M1.42M8.02M
Operating Cash Flow(60.25M)(74.11M)(79.74M)(46M)(47.84M)
Capital Expenditures(1.76M)(1.43M)(414K)00
Acquisitions (Net)0000(5.22M)
Purchases of Investments0(216.34M)(90.05M)(88.3M)(10.4M)
Sales of Investments0118.49M154.61M60.46M9.8M
Other Investing Activities000(7.07M)0
Investing Cash Flow(1.76M)(99.28M)64.14M(34.9M)(5.81M)
Debt Repayment000015M
Common Stock Issued131.3M037.56M065.84M
Common Stock Repurchased00(663K)00
Dividends Paid00000
Other Financing Activities582K1.1M39.09M054.63M
Financing Cash Flow131.74M1.1M75.98M0135.47M
Effect of Forex Changes00(406K)0604K
Net Change in Cash69.73M(172.3M)59.98M(80.91M)82.41M
Free Cash Flow(62.01M)(75.54M)(80.16M)(46M)(47.84M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.